Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q4 FY24 results · Jan–Mar 2024
Aarti Pharmalabs reported revenue from operations of ₹505.77 crore (up 4.3% from Q4 FY23) and net profit of ₹65.25 crore (up 52.2% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 505.77 | 485.06 | +4.3% | 448.69 | +12.7% |
| Other income | 2.03 | 0.74 | +174.9% | 1.39 | +46.0% |
| Total income | 507.80 | 485.80 | +4.5% | 450.08 | +12.8% |
| Profit before tax | 95.75 | 58.84 | +62.7% | 73.82 | +29.7% |
| Net profit for the period | 65.25 | 42.87 | +52.2% | 52.76 | +23.7% |
| Attributable to shareholders of the company | 64.36 | 42.87 | +50.1% | 52.76 | +22.0% |
| EPS, basic (₹) | 7.20 | 4.73 | +52.2% | 5.82 | +23.7% |
| Net margin (%) | 12.9 | 8.8 | 11.8 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 414.82 | 374.27 | +10.8% | 373.03 | +11.2% |
| Other income | 5.69 | 0.00 | — | 0.20 | 29x |
| Total income | 420.50 | 374.27 | +12.4% | 373.23 | +12.7% |
| Profit before tax | 91.28 | 56.74 | +60.9% | 67.44 | +35.4% |
| Net profit for the period | 63.02 | 39.99 | +57.6% | 48.19 | +30.8% |
| EPS, basic (₹) | 6.95 | 4.41 | +57.6% | 5.32 | +30.6% |
| Net margin (%) | 15.2 | 10.7 | 12.9 |
Consolidated
- Filed with BSE
- 15 May 2024, 09:21 IST
- Board meeting
- 13 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 May 2024, 09:21 IST
- Board meeting
- 13 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE